Peter Sagmeister, PhD.
Co-founder
Postdoctoral researcher at MIT.
- 20+ publications (800+ citations)
- 30+ conferences
- Inventor on multiple patents
Our Story
We believe that the way a drug is made should never limit its potential.
That shared conviction is what brought Bizon Labs together. As postdoctoral researchers at the Massachusetts Institute of Technology working across chemical engineering, drug delivery, and pharmaceutical manufacturing, we became increasingly convinced that some of the most important bottlenecks in medicine are not only biological, but also technological and manufacturing-related.
We chose to focus on drug delivery because it is one of the areas where we believe engineering can have the greatest impact. In lipid nanoparticles, small differences in how particles are formed can fundamentally change performance, yet current development workflows still offer limited control over the underlying process.
Bizon Labs was founded to address that gap. Our goal is to build technologies that give drug developers precise control over lipid nanoparticle formation, enabling better performance, more predictable process development, and a clearer path from scientific promise to real therapeutic impact.
